Circulating miR-30b levels increase during male puberty.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
May 2021
Historique:
received: 12 11 2020
accepted: 05 03 2021
pubmed: 6 3 2021
medline: 29 4 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

The role of miRNA as endocrine regulators is emerging, and microRNA mir-30b has been reported to repress Mkrn3. However, the expression of miR-30b during male puberty has not been studied. Circulating relative miR-30b expression was assessed in sera of 26 boys with constitutional delay of growth and puberty (CDGP), treated with low-dose testosterone (T) (n =11) or aromatase inhibitor letrozole (Lz) (n =15) for 6 months and followed up to 12 months (NCT01797718). The associations between the relative expression of miR-30b and hormonal markers of puberty were evaluated. During the 12 months of the study, circulating miR-30b expression increased 2.4 ± 2.5 (s.d.) fold (P = 0.008) in all boys, but this change did not correlate with corresponding changes in LH, testosterone, inhibin B, FSH, or testicular volume (P = 0.25-0.96). Lz-induced activation of the hypothalamic-pituitary-gonadal (HPG) axis was associated with more variable miR-30b responses at 3 months (P < 0.05), whereas those treated with T exhibited significant changes in relative miR-30b levels in the course the study (P < 0.01-0.05). Circulating miR-30b expression in boys with CDGP increases in the course of puberty, and appears to be related to the activity of the HPG axis.

Identifiants

pubmed: 33667194
doi: 10.1530/EJE-20-1307
pii: EJE-20-1307
doi:
pii:

Substances chimiques

MIRN30b microRNA, human 0
MicroRNAs 0
Testosterone 3XMK78S47O
Letrozole 7LKK855W8I
MKRN3 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

K11-K14

Auteurs

Tero Varimo (T)

New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland.

Yafei Wang (Y)

Stem Cells and Metabolism Research Program, Research Programs Unit, Helsinki, Finland.
Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Päivi J Miettinen (PJ)

New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland.

Kirsi Vaaralahti (K)

Stem Cells and Metabolism Research Program, Research Programs Unit, Helsinki, Finland.
Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Matti Hero (M)

New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland.

Taneli Raivio (T)

New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland.
Stem Cells and Metabolism Research Program, Research Programs Unit, Helsinki, Finland.
Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH